Detalles de la búsqueda
1.
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
Med J Aust
; 220(2): 80-90, 2024 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212673
2.
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Lancet
; 399(10336): 1718-1729, 2022 04 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35367007
3.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Lancet Oncol
; 23(11): 1378-1388, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36265502
4.
Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
Br J Cancer
; 126(3): 401-408, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34373567
5.
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.
Oncologist
; 25(3): e520-e527, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162809
6.
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.
BMC Cancer
; 18(1): 726, 2018 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29986670
7.
Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors).
Med J Aust
; 205(9): 418-424, 2016 Nov 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27809739
8.
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
J Clin Oncol
; 42(14): 1619-1624, 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38452313
9.
Safety of pembrolizumab while commencing treatment for hepatitis C with Harvoni (ledipasvir and sofosbuvir).
Intern Med J
; 48(12): 1542-1543, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30517998
10.
Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy.
Cancer Med
; 12(13): 14694-14706, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37184115
11.
Detection of metastases using circulating tumour DNA in uveal melanoma.
J Cancer Res Clin Oncol
; 149(16): 14953-14963, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37608028
12.
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
J Clin Oncol
; 41(1): 75-85, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35867951
13.
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Eur J Cancer
; 176: 207-217, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36202690
14.
Associations of Physical Activity and Exercise with Health-related Outcomes in Patients with Melanoma During and After Treatment: A Systematic Review.
Integr Cancer Ther
; 20: 15347354211040757, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34412527
15.
Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study.
Front Oncol
; 10: 1041, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32695680
16.
The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection.
Cancers (Basel)
; 12(12)2020 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33339135
17.
Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.
Oncotarget
; 11(44): 4016-4027, 2020 Nov 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33216826
18.
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
Clin Cancer Res
; 26(22): 5926-5933, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33067256
19.
Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies.
Oncotarget
; 10(2): 113-122, 2019 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30719207
20.
Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles.
Cancers (Basel)
; 11(2)2019 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-30769764